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INTRODUCTION 
Enhancing the effectiveness of aspirin by tailoring administration regimens is an important 
question amongst health professionals. We conducted a systematic review to evaluate the 
evidence on the effects of different aspirin regimens in terms of timing (chronotherapy) or 
frequency of dosing in the prevention of cardiovascular disease. Only 2 out of the 28 
included studies reported long-term cardiovascular outcomes highlighting an evidence gap 
that future research should address. The remaining 26 studies used surrogate outcomes. 
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INTRODUCTION 
Cardiovascular disease (CVD) continues to be a leading clinical and public health problem 
worldwide, accounting for around 17.5 million deaths each year (1). Once-daily 
administration of low-dose aspirin (around 75-100mg) is the most commonly used 
antiplatelet treatment for secondary prevention of CVD as it reduces the risk of major 
cardiovascular events (MACE) by 25% (2, 3). The use of aspirin in primary prevention of 
CVD has a more controversial risk-benefit profile and is not routinely recommended (4-6). 
Despite the known benefits of aspirin, some patients experience recurrences of 
ischemic events (4). Poor compliance with treatment may be one explanation (7, 8), 
however, differences in co-morbidities, co-medications and kinetics of aspirin targets could 
also account for a variable response (9, 10). Accelerated platelet function recovery may also 
account for variability in platelet responsiveness, especially in patients with increased 
platelet turnover, e.g. in diabetes, essential thrombocythaemia (ET) and coronary artery 
disease (CAD) (11-16). 
Chronotherapy studies have postulated that aspirin intake at bedtime instead of on 
awakening could potentially lead to greater benefits in some patients by reducing morning 
platelet reactivity, improving blood pressure (BP) profile, and subsequently reducing 
incidence of cardiovascular events during the high-risk morning hours (17-19). In addition, 
some evidence has suggested that increased dosing frequency may benefit patients with 
suboptimal response to aspirin or where aspirin treatment appears to have been ineffective 
(20, 21). In contrast, a less frequent administration of aspirin, e.g. every other day, could 
minimise long-term adverse events, such as bleeding, though it is currently not known in 
which patient groups this might be beneficial. 
Scoping searches identified no recent, methodologically robust systematic reviews 
on the timing and frequency of dosing of aspirin administration in primary and secondary 
prevention of CVD. A broad review with some systematic methodological elements was 
identified, which covered the chronotherapy aspect of a range of drugs, including aspirin 
(searches up to 2011) (22). However, the robustness of the overall findings was uncertain 
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due to methodological limitations in the review, including restrictions placed on publication 
language and date, and a lack of quality assessment of reviewed studies. A further 
systematic review and meta-analysis from 2011 on timing of aspirin administration was 
identified, however, this appears to be published in abstract form only and full details on 
methodology could not be ascertained (23). Thus, the aim was to undertake an up-to-date, 
methodologically robust systematic review of the evidence on alternative timing and dosing 
regimens of aspirin used in primary and secondary prevention of CVD. This was split into 
two research questions: 
• The effect of timing of aspirin intake (e.g. morning versus evening) on primary and 
secondary prevention of CVD. 
• The effect of altering the frequency of aspirin intake (e.g. once- versus twice-daily (or 
more) or alternate-day dosing) on primary and secondary prevention of CVD.  
 
TAXONOMY OF STUDIES ASSESSING ASPIRIN REGIMENS’ EFFECTIVENESS  
The search strategy identified 4,272 records; 28 studies were eligible for inclusion and 
informed the analysis (see Figure 1). 12 studies (19, 24-34) investigated the effects of 
aspirin when administrated once-daily in the morning/after awakening versus in the 
evening/at bedtime; 12 studies (15, 35-45) compared aspirin administration once-daily with 
two or more times daily; and 4 studies (46-49) compared once-daily versus alternate-day (or 
less frequent) aspirin dosing. Table 1 shows the main study characteristics. 
 
Studies reporting primary outcomes 
Morning versus evening administration 
No studies were identified that compared morning versus evening administration of aspirin 
and reported cardiovascular events or mortality in any population. 
 
Once- versus twice-daily (or more) administration 
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Only one study was identified. The UK transient ischemic attack (UK-TIA) trial published in 
1991 (44) randomised patients with a transient ischaemic attack (TIA) or minor ischaemic 
stroke to twice-daily aspirin (2x 600mg = 1200mg), once-daily aspirin (300mg) or placebo. 
There were no significant differences between aspirin regimens for vascular and non-
vascular deaths, stroke, myocardial infarction or MACE, though there were significantly 
fewer upper gastrointestinal symptoms with the lower once-daily dose regimen. This study 
was deemed to be at low risk of bias overall (see supplementary file Table 1); however, due 
to the substantial difference in overall daily dose, it was not possible to derive any 
conclusions for a twice- versus once-daily dosing regimen. 
   
Once-daily versus alternate-day (or less frequent) administration 
One RCT (48) from 1999 found a statistically significant reduction of MACE in patients with 
primary atrial fibrillation when 125mg aspirin was administered on alternate-days compared 
to once-daily; the difference between regimens was not statistically significant for ischaemic 
stroke. Due to the unclear risk of bias of the current study (see supplementary file Table 1) 
and the absence of additional studies supporting a possible benefit from an alternate-day 
aspirin administration in patients with atrial fibrillation, no firm conclusions could be drawn. 
 
Adverse events 
Five studies (19, 25, 28, 33, 35) (4 from morning versus evening, 1 from once- versus twice-
daily group) reported that patients did not experience any adverse events following different 
aspirin regimens but without any further details. Specific adverse events, including 
heartburn, headache, gastric and haemorrhagic side effects, were reported in 6 studies (24, 
26, 35, 36, 44, 48) (2 from morning versus evening, 3 from once- versus twice-daily, 1 from 
alternate-day group) with event frequencies similar across different aspirin regimens. The 
remaining 18 studies provided no details on adverse events during aspirin treatment. 
 
Studies reporting secondary/surrogate outcomes 
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24 of the 28 studies included in the analysis reported surrogate outcomes such as BP and 
PFTs. 2 further studies reported other outcomes such as frequency of cutaneous flushing 
(24) and incidence of colorectal cancer (47) in people with diabetes. 
 
Effect on blood pressure 
Morning versus evening administration 
12 studies (see Table 1) were identified: 9 were RCTs (4 parallel (19, 25, 28, 29) and 5 
cross-over (26, 27, 30, 31, 33)) and 3 non-randomised controlled trials (1 parallel (24) and 2 
cross-over (32, 34)). Studies were heterogeneous in terms of population (untreated or 
treated hypertension, CVD), duration of treatment (from 5-7 days to 1 year) and outcome 
(BP, PFT or cutaneous flushing).  
9/12 studies reported 24h or 48h mean ambulatory blood pressure measurements 
(ABPM) (19, 25-30, 33, 34). Of those, 4 parallel RCTs (19, 25, 28, 29) conducted by the 
same research group favoured aspirin administration in the evening, with most results being 
statistically significant (see Figure 2). All 4 studies included untreated grade 1 (mild) 
hypertensives or pre-hypertensives that were on average much younger compared to the 
populations in the cross-over trials discussed below. It has been suggested that lack of 
nocturnal BP decline (“non-dipping”) may be an independent indicator of increased 
cardiovascular risk (50); only 1/4 studies (19) performed a sub-group analysis in dipper 
versus non-dipper patients, which showed a similar benefit for evening intake. A further 
small, short-term cross-over trial (33), also in pre-hypertensives, found no difference 
between morning and evening intake.  
The 4 remaining cross-over studies (26, 27, 30, 34) found that the effect of aspirin 
was not influenced by the timing (see Figure 2). The populations included in these studies 
were treated hypertensives (with co-morbidities such as diabetes/renal failure (27) and 
obesity (34))  or individuals with already established CVD (26, 30). Patients in these studies 
were older compared to those in the parallel RCTs, and on co-medication for hypertension.  
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Analysis of the mean nocturnal measurements in 8/9 studies (19, 25-28, 30, 33, 34) 
(data not shown) mirrored the 24hr mean ABPM results. Data from studies reporting 
outcomes other than ABPM are shown in supplementary file Table 2 (24, 26, 30-32). 
It was speculated that study design could have an effect on findings, as the 4 studies 
(19, 25, 28, 29) showing a benefit on BP from evening aspirin administration were parallel 
trials, whilst the 5 studies (26, 27, 30, 33, 34) showing no difference had a cross-over 
design. However, 3/5 (26, 30, 33) cross-over trials either had a washout period or accounted 
for potential treatment period effects in their analysis (see supplementary file Table 1 for full 
details of quality assessment). There were no other obvious methodological differences, e.g. 
in terms of % of drop-outs,  between the parallel and cross-over studies, with most being 
open-label trials, but with blinded endpoint assessment (PROBE design). All but 1 study (30) 
did not conduct an intention-to-treat analysis. Overall it appears more likely that differences 
in study population account for the differences between studies as opposed to 
methodological issues, though a lack of rigour in some methodological aspects may have 
influenced the robustness of findings. 
 
Effect on platelet function 
Morning versus evening administration 
3 cross-over studies (26, 30, 32) reported platelet function inhibition as related to timing of 
aspirin administration (see supplementary file Table 2). In one trial (30), no difference was 
apparent, while in another study (26), evening administration of aspirin statistically 
significantly reduced morning platelet reactivity in all patients except those with diabetes. An 
inhibitory effect of evening administration on platelet reactivity was also observed in the Li et 
al. trial (32). 
 
Once- versus twice- daily (or more) administration  
The 11 studies (15, 35-43, 45) (see Table 1) comparing a different frequency of daily dosing 
were heterogeneous in terms of study design, duration of treatment and population 
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(diabetes, CAD, CVD, ET); all were short-term studies with up to 2 months per treatment 
period reporting as their main outcome PFT results, mainly light transmission aggregometry 
(LTA), serum thromboxane levels and VerifyNow Aspirin. Where possible, these results have 
been presented in forest plots (see Figures 3, 4), with the remaining results tabulated (see 
supplementary file Tables 3-7). A distinction has been made between studies comparing the 
same or a different overall daily dose.  
For comparisons of the same overall dose, most results across 5 studies (36, 37, 39, 
40, 42) did not show statistically significant differences in platelet function; 2 studies (15, 39) 
found a significant difference (favouring twice-daily dosing) with one but not the other of two 
PFTs used respectively. There is thus little evidence to suggest a potential benefit from 
twice-daily dosing in these populations (Type2 diabetes mellitus (T2DM) with or without 
CAD/CVD, or ischemic heart/cerebrovascular disease (IHD/ICD)). The daily dose in all the 
studies was higher (≥100mg) than what could be considered standard-of-care (up to 162mg 
depending on the country of study). 
Two studies (38, 41) included only ET patients and suggested a potential benefit 
from twice-daily dosing based on PFTs (see Figure 3 and supplementary file Tables 4, 5), 
with most findings statistically significant. Increased platelet turnover may explain a potential 
benefit from twice-daily dosing in this population (51, 52). 
Where the combined (split) dose was higher than the single dose, there were mostly 
statistically significant differences in platelet function in favour of split dosing across 
populations: for 4/5 studies (15, 36, 41, 42) (serum thromboxane; see Figure 4 and 
supplementary file Table 4), 3/4 studies (36, 37, 41) (VerifyNow; see Figure 4 and 
supplementary file Table 5), 2/2 studies (35, 36) (PFA-100; see supplementary file Table 6) 
and 3/3 studies (36, 42, 43) (WBA; see supplementary file Table 7). This was not the case 
for LTA as 4/5 studies (36, 37, 41, 43) did not find a significant difference between aspirin 
regimens (see Figure 3 and supplementary file Table 3). One study (43) found a significant 
difference in favour of twice-daily dosing even though the overall dose (2x 75mg) was 
smaller than the once-daily dose (320mg). Another study (45) suggested that aspirin once-
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daily (125mg) compared to three times daily (3x 125mg) improved circadian rhythm 
fluctuations of haemocoagulation. Overall it was not possible, however, to distinguish 
between the potential impacts from a different daily dose and/or the split dosing element. 
There were a number of methodological concerns across studies, which may 
influence the robustness of findings, e.g. a lack of washout period and a lack of detail on 
blinding and intention-to-treat analysis (see supplementary file Table 1). The overall findings 
of a potential benefit of twice-daily dosing in an ET population compared to the other 
populations should therefore be seen as indicative only; however, it is also unlikely that the 
difference observed was due to particular methodological differences between study 
designs. 
 
Once-daily versus alternate-day (or less frequent) administration 
The 3 studies (46, 47, 49) identified in this group that reported secondary outcomes were 
extremely heterogeneous in terms of study design (prospective versus retrospective, cohort, 
non-randomised trials), population (cerebral thrombosis, high on-aspirin treatment platelet 
reactivity patients, diabetes), aspirin dose/frequency, duration of treatment and outcome 
measure (PFT, colorectal cancer; see Table 1). That limited evidence precluded any 
conclusions regarding the effectiveness of a daily versus alternate-day regimen.  
 
CONCLUSIONS AND FUTURE PROSPECTS 
Summary of evidence 
Despite analysing 28 controlled studies, this systematic review has failed to find any 
substantial evidence on the effect of different aspirin regimens on long-term clinical 
outcomes in individuals prescribed aspirin for primary or secondary prevention of CVD. Only 
2/28 studies reported long-term cardiovascular outcomes: the large UK-TIA trial (44) (once- 
versus twice-daily), and found no overall difference in cardiovascular events or deaths during 
a 4 years follow-up in a TIA population; there was a substantial difference in overall daily 
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aspirin dose (300mg versus 2x 600mg). In the Posada et al. trial (48) low-dose aspirin given 
on alternate-days was proven to be more efficient than daily dosing in preventing MACE in 
people with atrial fibrillation. The remaining 26 studies encompassed a range of different 
populations with a variety of co-morbidities; these studies presented secondary/surrogate 
outcomes mainly relating to BP and/or PFTs. There was some evidence, based on 4 parallel 
RCTs (total n=835), that evening compared to morning intake of aspirin significantly reduced 
ambulatory BP in untreated mild hypertensives and pre-hypertensives. In a population of 
treated hypertensives or in those with established CVD, aspirin administration either in the 
morning or in the evening did not seem to have a differential effect on ambulatory BP levels 
(based on 4 cross-over studies, total n=432).  
A limited amount of evidence (from 2 cross-over trials n=47-53) suggested a potential 
benefit from twice-daily dosing for ET patients based on PFT results. There was little 
evidence to suggest a potential benefit from twice-daily (or more) dosing in other populations 
(T2DM (with or without CAD/CVD) or with IHD/ICD). Several studies reporting once- versus 
twice-daily (or more) dosing did not compare the same overall daily dose, therefore 
confounding evaluation of the split dosing aspect.   
There was very limited evidence on once-daily versus alternate-day aspirin intake 
and studies were clinically and methodologically heterogeneous; meaningful conclusions 
could not be drawn. 
 
Strengths and limitations of the systematic review and available data 
To our knowledge, this is the first comprehensive systematic review looking at different 
timing and dosing frequencies of aspirin administration in a diverse patient population. A 
robust systematic review methodology and sensitive search strategy mean that it is unlikely 
that relevant studies have been missed, though formal assessment of publication bias was 
not feasible. Heterogeneity between studies, particularly in terms of population, precluded 
pooling in meta-analysis, but results were presented graphically where possible and 
supplemented with tabulated results.  
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Some methodological concerns were noted across included studies but the main 
limitation of the available evidence was the lack of long-term studies in patients prescribed 
aspirin for primary or secondary prevention that report clinical outcomes. Whilst surrogate 
outcomes such as BP and PFTs might be considered to be associated with future risk of 
cardiovascular events, these cannot replace traditional clinical endpoints and have their own 
limitations. However, findings from such studies can be used to inform the feasibility and 
design of longer-term studies. Further, compliance may be an issue in studies assessing 
dosing frequency regimens. Although compliance was assessed in most of the included 
studies, findings were generally not clearly reported or not reported at all. 
 
Implications of findings 
Despite the large number of patients on aspirin currently being managed in primary care, this 
systematic review has highlighted the lack of evidence on the effect of different aspirin 
regimens, in terms of timing and frequency of administration, on long-term cardiovascular 
outcomes. Those differences in effect observed based on surrogate end points should be 
interpreted with caution due to the limited evidence in different populations and some 
methodological concerns within studies. Thus, the current level of evidence does not warrant 
a change in clinical practice.  
The studies conducted by the Hermida et al. group were suggestive of a favourable 
effect of evening aspirin intake on BP in untreated hypertensives; however, these are not 
necessarily representative of patients most at risk of cardiovascular events and such findings 
are unlikely to have an impact on current recommendations. Indeed, according to European 
and American guidelines, aspirin is not recommended in low-to-moderate risk hypertensives 
(without co-morbidities) aged below 50 years (3, 53, 54). The studies finding no difference in 
effect of morning or evening dosing on BP were in patients already treated with BP lowering 
agents. It may be that any potential differences in effect from morning versus evening aspirin 
intake are too small to be observed where BP is already controlled by another agent, i.e. 
there may be a ceiling effect to how much difference timing of aspirin can make.  
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A limited amount of evidence suggests that patients with ET may benefit from twice-
daily dosing. There currently appear to be no recommendations on the frequency of aspirin 
administration in this population, and the evidence identified in this systematic review is 
relatively sparse, but future research focusing on longer-term outcomes may be worthwhile 
in patients suffering from ET.  
  
Unanswered questions and future research 
Whether or not aspirin enhances the effects of hypertensive medication in a population of 
essential hypertensives is still uncertain. A systematic review summarising the data on the 
potential antihypertensive effects of aspirin found that short-term use of low-dose aspirin 
doesn’t seem to modify the effect of antihypertensive drugs (55); however, an increase in the 
risk of hypertension (about 20%) among long-term aspirin users was observed. Therefore, 
the effect of aspirin on BP is unclear, and this mechanism is unlikely to be a major 
contributor to aspirin’s efficacy in prevention of major adverse cardiovascular events, in 
addition to its well-characterised effect on platelet function.    
A significant number of studies investigating the split dosing regimen neither kept the 
overall daily dose the same between once- and twice-daily groups nor used the standard 
care low-dose of aspirin; thus, this is something that investigators need to consider when 
designing new trials. While most guidelines recommend doses of 75-100mg daily (3, 53, 56), 
some of the studies have used doses in excess of 325mg daily. At low doses, the effect of 
aspirin is predominantly on the platelet cyclooxygenase I (COX-1) enzyme, with little to no 
effect on inflammatory pathways mainly mediated through inducible COX-2 (57). However, 
at doses in excess of 325mg daily, especially when multiple doses per day are administered, 
the antithrombotic effect cannot be dissociated with the anti-inflammatory effect of aspirin.  
Although most included studies used anti-thrombotic aspirin doses (75-325mg daily), some 
studies in the context of cerebrovascular disease used doses in excess of 325mg (44, 46). It 
is therefore possible that the effect of aspirin in this context may be due to other 
mechanisms of action than its intended use as an antithrombotic agent. In addition, although 
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most of the studies mention that patients did not show any adverse events during aspirin 
therapy, the use of high doses could potentially increase the risk for bleeding and change 
the balance between any positive and harmful effects that aspirin might have.  
A thorough search in ongoing trial registries has identified only one study that could 
potentially address some of the questions above. An ongoing trial by Herimida R.C. and 
Ayala D.E. (NCT 00725127) is investigating the effects of chronotherapy with low-dose 
aspirin in a population with impaired fasting glucose or T2DM on primary prevention of CVD. 
This study is unique in focusing on cardiovascular, cerebrovascular and renal fatal and non-
fatal events after 5 years of aspirin chronotherapy. No ongoing trials were found in patients 
in other important risk categories (such as AF, stroke and heart failure) or in populations 
using aspirin for secondary prevention and this could be an unmet research need. 
In conclusion, enhancing the effectiveness of aspirin for the prevention of CVD by 
tailoring administration regimens is an important question, and one that has been addressed 
in 28 studies with heterogeneous populations. The vast majority used surrogate outcomes 
and based on these there is limited evidence indicative of a benefit from evening 
administration in a primary prevention population; this could not, however, be demonstrated 
in a population taking aspirin for secondary prevention. There is also a clear evidence gap in 
terms of the effect of different aspirin regimens on long-term cardiovascular outcomes in 
both primary and, perhaps more importantly, in secondary prevention. Future randomised 
controlled trials, which control for daily aspirin dose in addition to timing and frequency, could 
assess the long-term clinical utility of alternative aspirin dosing strategies in this population. 
 
SYSTEMATIC REVIEW STRATEGY  
Systematic review methodology and reporting were based on the Cochrane Collaboration 
handbook (58) and the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) (59). The review protocol was registered with PROSPERO 
(CRD42014010596) and published in BMC Systematic Reviews (60). 
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 Search strategy  
MEDLINE, MEDLINE In Process, EMBASE, CINAHL, The Cochrane Library, Science 
Citation and Conference Proceedings Citation Index (Web of Science), and ZETOC (British 
Library) were searched with no language restrictions to June 2015 (see supplementary file 
Appendix 1 for sample search strategy). Reference lists of relevant studies were checked. 
Selected websites and clinical trials registries were searched for unpublished and ongoing 
studies.  
 
Selection criteria  
Two reviewers independently screened articles for eligibility using predetermined criteria. 
Any controlled (non-)randomised studies were eligible if they included patients prescribed 
aspirin for primary or secondary prevention of CVD. Study selection was not restricted by 
underlying conditions (e.g. established CVD, diabetes, hypertension, dyslipidaemia, 
essential thrombocythaemia or atrial fibrillation). Studies involving patients in an acute (post-
operative) setting were not analysed (59-61-63). 
There were no restrictions on doses being compared provided there was a difference 
in dosing timing (e.g. in the morning compared to the evening) or frequency (e.g. twice or 
more per day versus once per day, alternate-day versus every day). There were no 
restrictions on study selection by outcome report. For the review, outcomes such as 
cardiovascular events, mortality, and adverse events (e.g. bleeding) were considered of 
primary importance, and surrogate end points such as BP and platelet function measured 
with a platelet function test (PFT) were secondary. 
 
Data extraction and quality assessment 
Data extraction was conducted by one reviewer using a standardised, piloted data extraction 
form and checked by a second reviewer. Study authors were contacted if further information 
or clarifications were required. Quality assessment was based on the Cochrane risk of bias 
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tool (64). For cross-over trials additional risk of bias, such as carry-over effects, were 
assessed (see supplementary file Table 1). 
 
Data synthesis and analysis 
Data for analysis was taken as reported from the published articles or as supplied by the 
authors. Heterogeneity between studies in design, population characteristics and duration of 
treatment precluded meta-analysis. However, where sufficient data were available, results 
for each outcome were presented in forest plots for illustrative purposes without a pooled 
summary estimate. Results not represented in forest plots were tabulated and described. It 
was not possible to formally assess the potential for publication bias. 
 
ABBREVIATIONS 
ABPM: ambulatory blood pressure measurements 
BP: Blood pressure 
CAD: coronary artery disease 
CVD: Cardiovascular disease 
ET: essential thrombocythaemia 
IHD/ICD: ischemic heart/cerebrovascular disease 
MACE: major cardiovascular events  
PFT: Platelet function test 
RCT: Randomised controlled trial 
T2DM: Type 2 diabetes mellitus 
TIA: transient ischemic attack 
UK-TIA: United Kingdom - transient ischemic attack 
 
STUDY HIGHLIGHTS 
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WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? Routine use of daily low-dose 
aspirin is known to be beneficial for secondary prevention of cardiovascular disease, though 
there is uncertainty regarding primary prevention. 
WHAT QUESTION DID THIS STUDY ADDRESS? Are there more effective aspirin regimens 
– in terms of timing and frequency – than once-daily morning dosing?  
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE? The first comprehensive systematic 
review of the evidence on different aspirin regimens used in primary and secondary 
prevention of cardiovascular disease. Limited evidence based on surrogate endpoints is 
suggestive of a benefit of evening/twice-daily dosing regimens in specific (primary 
prevention) populations; a small amount of evidence does not suggest a differential effect in 
secondary prevention. 
HOW THIS MIGHT CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL 
SCIENCE? There is an evidence gap in terms of the effect of different aspirin regimens on 
long-term cardiovascular outcomes. This calls for better-standardised studies to assess the 
long-term clinical utility of alternative aspirin dosing strategies in primary and secondary 
prevention of cardiovascular disease. The current level of evidence does not warrant a 
change in clinical practice. 
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Figure 1. PRISMA flow diagram for study selection 
 
Figure 2. 24hr mean systolic and diastolic ambulatory BP differences between 
morning and evening aspirin intake in chronotherapy studies.  
CI, confidence interval; CVD, cardiovascular disease; DBP, diastolic blood pressure; HTN, 
hypertension; RCT, randomised controlled trial; SBP, systolic blood pressure; SD, standard 
deviation; WMD, weighted mean difference; astudies reporting 48hr mean systolic and 
diastolic ambulatory BP. 
 
Figure 3. Light transmission aggregometry (LTA) data from studies looking at 
different aspirin dosing frequencies. 
Forest plot illustrating mean difference in percentage of platelet aggregation in response to 
0.5-1.3mM arachidonic acid (AA) as measured by LTA. CAD, coronary artery disease; CI, 
confidence interval; CVD, cardiovascular disease; ET, essential thrombocythaemia; RCT, 
randomised controlled trial; T2DM, type 2 diabetes mellitus; WMD, weighted mean 
difference. 
 
Figure 4. Serum TxB2 and VerifyNow data from studies looking at different aspirin 
dosing frequencies. 
Forest plot on the left illustrating mean difference in serum thromboxane levels (ng/ml) and 
forest plot on the right illustrating mean difference in aspirin reaction units (ARU) as 
measured with the VerifyNow analyser. CAD, coronary artery disease; CI, confidence 
interval; CVD, cardiovascular disease; ICD, ischemic cerebrovascular disease; IHD, 
ischemic heart disease; RCT, randomised controlled trial; T2DM, type 2 diabetes mellitus; 
WMD, weighted mean difference. ano VerifyNow data available for those studies; bno serum 
TxB2 data available for that study. 
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3.50 (2.06, 4.94) 
-0.10 (-2.59, 2.39) 
-0.60 (-2.53, 1.33) 
5.00 (2.95, 7.05) 
5.50 (3.91, 7.09) 
6.10 (4.60, 7.60) 
-0.60 (-2.33, 1.13) 
-0.70 (-4.51, 3.11) 
1.00 (-0.81, 2.81) 
Study Design Age  
(mean ± SD) 
Aspirin  
Dose 
Duration  
of therapy 
WMD (95% CI) 
24hr mean  DBP 
NOTE: Weights are from random effects analysis 
Pre-hypertension 
Hermida 2009 
Untreated HTN 
Hermida 1997 
Hermida 2005(b) 
Ayala 2010 
Snoep 2009 
Treated HTN 
Dimitrov 2011 
Suomela 2015 
CVD 
Lafeber 2014 
Bonten 2015 
Parallel RCT 
Parallel RCT 
Parallel RCT 
Parallel RCT 
Cross-over RCT 
Cross-over RCT 
Cross-over  
non-randomised 
Cross-over RCT 
Cross-over RCT 
43.0 ± 13.0 
21.8 ± 1.7 
44.6 ± 12.5 
44.1 ± 13.2 
58.4 ± 6.8 
65 ± 9 
64.9 ± 7.6 
67 ± 8 
64 ± 7 
100mg 
100mg 
100mg 
100mg 
100mg 
106 ± 50mg 
50-250mg 
75mg as polypill 
100mg 
3 months 
1 week 
3 months 
3 months 
2 weeks 
1 month 
3 months –  
1 year 
6-8 weeks 
3 months 
WMD>0 favours evening aspirin intake 
3.40 (-0.84, 7.64) 
0.00 (-3.88, 3.88) 
-0.80 (-4.19, 2.59) 
0.00 (-2.15, 2.15) 
WMD (95% CI) 
7.00 (4.67, 9.33) 
7.60 (5.71, 9.49) 
7.30 (5.65, 8.95) 
-0.40 (-2.55, 1.75) 
-0.10 (-6.88, 6.68) 
    0 -10 10 
24hr mean SBP 
    0 -10 10 
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NOTE: Weights are from random effects analysis 
 
Same overall dose 
Dillinger 2012(a) (cross-over RCT) 
Bethel 2015 (cross-over RCT) 
Capodanno 2011 (cross-over non-random.) 
Capodanno 2011 (cross-over non-random.) 
Different overall dose 
Spectre 2011 (cross-over RCT) 
Capodanno 2011 (cross-over non-random.) 
Dillinger 2012(b) (cross-over non-random.) 
Dillinger 2012(b) (cross-over non-random.) 
Study 
T2DM with CAD 
T2DM without CVD 
T2DM with CAD 
T2DM with CAD 
T2DM + vascular complications 
T2DM with CAD 
ET 
ET 
Main underlying  
disease 
150mg vs 2x 75mg 
200mg vs 2x 100mg 
162mg vs 2x 81mg 
325mg vs 2x 162mg 
75mg vs 2x 75mg 
81 mg vs 2x 81mg 
250mg vs 2x 100mg 
100mg vs 2x 100mg 
Aspirin Dose 
mean 10 ± 2 days 
2 weeks 
1 week 
1 week 
2 weeks 
1 week 
mean 15 ± 5 days 
mean 15 ± 5 days 
Duration  
of therapy 
8.50 (2.83, 14.17) 
2.00 (-4.12, 8.12) 
0.00 (-0.38, 0.38) 
0.00 (-0.69, 0.69) 
-0.20 (-4.06, 3.66) 
0.00 (-0.45, 0.45) 
52.00 (43.39, 60.61) 
56.00 (49.07, 62.93) 
WMD (95% CI) 
LTA (% aggregation) 
WMD>0 favours twice-daily aspirin intake 
Bethel 2015 (crossover RCT) T2DM without CVD 100mg vs 2x 100mg 2 weeks 2.00 (-3.73, 7.73) 
    
-63 0 63 
This article is protected by copyright. All rights reserved.
NOTE: Weights are from random effects analysis 
Same overall dose 
Santos 2006 (parallel RCT) 
Santos 2006 (parallel RCT) 
Bethel 2015 (cross-over RCT) 
Capodanno 2011  
(cross-over non-random.) 
Capodanno 2011  
(cross-over non-random.) 
Different overall dose 
Santos 2006 (parallel RCT) 
Bethel 2015 (cross-over RCT) 
Capodanno 2011  
(cross-over non-random.) 
Study 
IHD or ICD 
IHD or ICD 
T2DM without CVD 
T2DM with CAD 
T2DM with CAD 
IHD or ICD 
T2DM without CVD 
T2DM with CAD 
Main underlying  
disease 
100mg vs 2x 50mg 
200 or 300mg vs 2x 100mg 
200mg vs 2x 100mg 
162mg vs 2x 81mg 
325mg vs 2x 162mg 
50mg vs 2x 50mg 
100mg vs 2x 100mg 
81 mg vs 2x 81mg 
Aspirin Dose 
≥ 2 months 
≥ 2 months 
2 weeks 
1 week 
1 week 
≥ 2 months 
2 weeks 
1 week 
Duration  
of therapy 
WMD (95% CI) 
Serum TxB2 (ng/ml) 
WMD>0 favours twice-daily aspirin intake 
0.41 (-0.08, 0.90) 
0.08 (-0.21, 0.37) 
0.01 (-0.03, 0.05) 
0.00 (-0.01, 0.02) 
0.07 (0.01, 0.14) 
3.00 (-0.20, 6.20) 
3.34 (2.01, 4.67) 
4.90 (0.11, 9.69) 
    
0 -10 10 
VerifyNow (ARU) 
14.00 (-16.33, 44.33) 
12.00 (-20.58, 44.58) 
8.00 (-26.14, 42.14) 
32.00 (0.64, 63.36) 
35.00 (6.32, 63.68) 
9.00 (-26.46, 44.46) 
    0 -70 70 
WMD (95% CI) 
Capodanno 2011  
(cross-over non-random.) 
T2DM with CAD 162mg vs 2x 162mg 1 week 
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Table 1. Main characteristics of included studies 
Table 1. Main characteristics of included studies 
a. Morning versus evening aspirin administration 
 Study/ year/ 
country 
CVD 
prevention 
Main 
underlying 
condition 
Age, years 
(mean ± 
SD) 
Study arms (n=) Aspirin dose/ frequency 
Duration of 
therapy 
Outcome 
measure 
Parallel RCTs 
Hermida et 
al., 1997, 
Spain 29 
Primary Untreated grade 
1 (mild) 
essential 
hypertension 
21.8 ± 1.7 1.  2hr after awakening 
(n=4) 
2.  7-9hr after awakening 
(n=6) 
3.  2hr before bedtime 
(n=8) 
100mg OD 1 week Ambulatory 
BP 
Hermida et 
al., 2005(b), 
Spain 19 
Primary Untreated grade 
1 (mild) 
essential  
hypertension 
44.6 ± 12.5 1.  On awakening (n=126) 
2.  At bedtime (n=131) 
Subgroup for (non-)dippers 
100mg OD 3 months Clinic and 
ambulatory 
BP 
Hermida et 
al., 2009, 
Spain 28 
Mainly 
Primary 
Pre- 
hypertension 
43.0 ± 13.0 1.  On awakening + HDR 
(n=61) 
2.  At bedtime + HDR 
(n=59) 
3.  HDR only (n=124) 
100mg OD 3 months Clinic and 
ambulatory 
BP 
Ayala & 
Hermida, 
2010, Spain 
25 
Mainly 
Primary 
Untreated grade 
1 (mild) 
essential  
hypertension 
44.1 ± 13.2 1.  On awakening (n=159) 
2.  At bedtime (n=157) 
Also subgroup for sex 
100mg OD 3 months Clinic and 
ambulatory 
BP 
Cross-over RCTs 
Snoep et al., 
2009, 
Netherlands 
33 
Primary Untreated grade 
1 (mild) 
essential  
hypertension 
58.4 ± 6.8 1.  On awakening (n=16) 
2.  At bedtime (n=16) 
100mg OD 2 weeks Ambulatory 
BP 
Dimitrov et 
al., 2012, 
France 27 
Primary Treated 
essential  
hypertension   
65.0 ± 9.0 1.  On awakening (n=75) 
2.  At bedtime (n=75) 
106 ± 50mg 
OD (mean ± 
SD) 
1 month Ambulatory 
BP 
Lee et al., 
2011, Korea 
31 
Mainly 
Primary 
Treated 
essential  
hypertension   
54.8 ± 7.8 1.  On awakening (n=109) 
2.  At bedtime (n=108) 
Subgroup for (non-)dippers 
100mg OD 12 weeks Clinic BP 
Lafeber et 
al., 2015, 
Netherlands 
30 
Mainly 
Secondary 
Established 
CVD or at high 
risk of having a 
CV event 
67.0 ± 8.0 1.  Morning polypill (n=78) 
2.  Evening polypill (n=78) 
3.  Polypill individual 
agents(n=78) 
Polypill 
containing 
75mg aspirin 
OD 
 
6-8 weeks Clinic and 
ambulatory 
BP;  PFT 
(VerifyNow) 
Bonten et al., 
2015, 
Netherlands 
26 
Primary and 
secondary 
Mixed 
population 
already using 
low-dose aspirin 
for prevention of 
CVD 
64.0 ± 7.0 1.  1hr after awakening 
(n=263) 
2.  1hr before bedtime 
(n=263) 
 
100mg OD 3 months Clinic and 
Ambulatory 
BP; PFT 
(VerifyNow) 
Parallel non-randomised controlled trials 
Alves et al., 
2008, 
Austria/ 
Germany/ 
Ireland/ 
Portugal/ 
Switzerland 
24 
Primary and 
secondary 
Elevated 
cardiovascular 
risk mainly due 
to CVD or 
T2DM 
61.4 ± 10.6 
(morning 
study arm), 
60.4 ± 10.7 
(evening 
study arm) 
1.  In the morning (n=227) 
2.  In the evening (n=312) 
 
75-100mg OD  15 weeks Frequency of 
cutaneous 
flushing 
Cross-over non-randomised controlled trials 
Li et al., 
2010, China 
32 
Secondary Acute coronary 
syndrome  
54.9 ± 10.2 1.  On awakening (n=30) 
2.  At bedtime (n=30) 
100mg OD 5-7 days PFT (WBA) 
Suomela et 
al., 2015, 
Finland 34 
Primary Treated 
essential  
hypertension   
64.9 ± 7.6 1.  On awakening (n=32-
34) 
2.  At bedtime (n=32-34) 
50 – 250mg 
OD 
3 months – 1 
year 
Clinic, home 
and 
ambulatory 
BP 
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b. Once- versus twice-daily (or more) aspirin administration 
Study/ year/ 
country 
CVD 
prevention 
Main 
underlying 
condition 
Age, years 
(mean ± SD) Study arms (n=) 
Duration of 
therapy Outcome measure 
Parallel RCTs 
UK-TIA study 
group, 1991, 
UK 44 
Secondary Recent TIA or 
minor ischaemic 
stroke 
60 ± 8.92 (OD 
study arm) and 
59.9 ± 9.16 (BID 
study arm) 
 
1.  300mg OD (n=806) 
2.  600mg BID (n=815) 
 
Mean 4 years 
(1-7) 
Mortality, 
ischemic/haemorrhagic 
stroke, MI, MACE, 
bleeding 
Zaslavskaia 
et al., 2002, 
Russia and 
Kazakstan 45 
Assume 
primary  
IDDM 23.3 ± 7.7 1.  125mg OD (n=15) 
2.  125mg TID (n=15) 
 
16 days 24hr profile of 
hemocoagulation 
Rocca et al., 
2012, Italy 15 
Primary and 
secondary 
T2DM Median (IQR) 
64.6 (60.7-69.0) 
1.  100mg OD (n=11) 
2.  200mg OD (n=11) 
3.  100mg BID (n=11) 
Subgroup without T2DM 
29 days PFT (VerifyNow, 
serum/urinary TxB2) 
Cross-over RCTs 
Spectre et 
al., 2011, 
Sweden 43 
Primary T2DM with 
micro- or macro-
vascular 
complications  
Median (range) 
64 (51-75) 
1.  75mg OD (n=24) 
2.  75mg BID (n=25) 
3.  320mg OD (n=24) 
2 weeks PFT (WBA, IMPACT-R, 
LTA), urinary TxB2, 
clinic BP 
Pascale et 
al., 2012, 
Italy 41 
Mainly 
primary 
ET with aspirin 
insensitive-
platelet TxB2 ≥ 4 
ng/ml 
Median (IQR) 51 
(29-67) 
1.  EC 200mg OD 
(n=15-21) 
2.  EC 100mg BID 
(n=15-21) 
3.  Plain 100mg OD 
(n=15-21) 
4.  EC 100mg OD (usual 
practice) (n=15-21) 
 
7 days PFT (LTA, VerifyNow, 
serum/urinary TxB2) 
Dillinger et 
al., 2012 (a), 
France 39 
Secondary T2DM with CAD  64 ± 10 1.  150mg OD (n=92) 
2.  75mg BID (n=92) 
10 ± 2 days 
(mean ± SD) 
PFT (LTA, PFA-100) 
Bethel et al., 
2016, UK 36 
Primary T2DM without 
CVD 
51 ± 7 1.  100mg OD (n=24) 
2.  200mg OD (n=24) 
3.  100mg BID (n=24) 
 
2 weeks PFT (VerifyNow, WBA, 
LTA, PFA-100, 
serum/urinary TxB2) 
Cross-over non-randomised controlled trials 
DiMinno et 
al., 1986, 
U.S.A. 40 
Mainly 
secondary 
Diabetes 39-51 (range) 1.  100mg OD (n=10) 
2.  25mg QID (n=10) 
3.  330mg OD (n=10) 
4.  100mg QID (n=10) 
4 weeks PFT (LTA, serum TxB2) 
Santos et al., 
2006, Spain 
42 
Secondary Ischemic heart 
disease (IHD) or 
ischemic 
cerebrovascular 
disease (ICD) 
IHD: 63.79 ± 
10.00; ICD: 63.92 
± 10.34  
500mg 2-week intervals 
plus: 
1.  50mg OD (n=31) 
2.  100mg OD (n=33) 
3.  50mg BID (n=78) 
4.  100mg BID (n=95) 
Or 200-300mg OD 
(usual practice) (n=206) 
≥2 months PFT (WBA, serum TxB2) 
Addad et al., 
2010, 
Tunisia 35 
Secondary CAD with 
diabetes 
58.4 ± 7.7  1.  100mg OD (n=25) 
2.  100mg BID (n=17) 
10 days PFT (PFA-100) 
Capodanno 
et al., 2011, 
U.S.A. 37 
Secondary T2DM with CAD  59 ± 7 1.  81mg OD (usual 
practice) (n=20) 
2.  81mg BID (n=20) 
3.  162mg OD (n=20) 
4.  162mg BID (n=20) 
5.  325mg OD (n=20) 
 
1 week PFT (LTA, VerifyNow, 
serum TxB2) 
Dillinger et 
al., 2012 (b), 
France 38 
Secondary ET 62 ± 17 1.  100mg OD (n=32) 
2.  250mg OD (n=32) 
3.  100mg BID (n=32) 
 
 
 
 
15 ± 5 days 
(mean ± SD) 
PFT (LTA) 
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BID, twice-daily; BP, blood pressure; CAD, coronary artery disease; CV, cardiovascular; CVA, Cerebrovascular accident; CVD, cardiovascular 
disease; EC, enteric coated aspirin; ET, essential thrombocythaemia; HAPS, high on-aspirin treatment platelet reactivity; HDR, non-
pharmacological hygienic-dietary recommendations; IDDM, insulin-dependent diabetes mellitus; IQR, interquartile range; LTA, light transmission 
aggregometry; MACE, major adverse cardiac event; MEA, multiple electrode platelet aggregometry; MI, myocardial infarction; OD, once-daily; 
PFT, platelet function test; QID, four times a day; RCT, randomised controlled trial; SD, standard deviation; T2DM, Type 2 diabetes mellitus; TIA, 
transient ischaemic attack; TID, three times a day; TxB2, thromboxane B2; WBA, whole blood aggregometry.  
 
c. Once-daily versus alternate-day (or less frequent) aspirin administration 
Study/ year/ 
country Design 
Main 
underlying 
condition 
Age, years 
(mean ± 
SD) 
Reason for 
aspirin 
administration 
Aspirin dose 
/frequency 
Duration of 
therapy/ 
follow up 
Outcome 
measure 
Lejeune et 
al., 1988, 
France 46 
Series of 
sequential 
intervention
s given to 
one group of 
patients; 
non-
randomised 
Cerebrovascular 
accident of 
atheromatous 
ischemic origin 
65.0 Secondary 
prevention of CVD 
0.3g, 0.5g and 1-
3g daily or every 
second day 
(n=14-17) 
2 weeks/8 
months after 
last visit 
Bleeding time 
(Ivy method) & 
PFT 
(Salzman’s 
method, LTA) 
Posada et 
al., 1999, 
Spain 48 
Parallel 
RCT 
Primary atrial 
fibrillation  
62.0 Primary & 
secondary 
prevention of CVD 
125mg daily 
(n=104) or on 
alternate-days 
(n=90) 
Long-term 
treatment /550 
days (mean) 
Death, CVA, 
MACE and 
compliance 
Temperilli et 
al., 2015, 
Italy 49 
Retrospectiv
e 
comparison 
of two non-
concurrent 
treatment 
groups 
HAPS patients 
defined by 
serum TxB2 >3.1 
ng/ml 
68.3 ± 11.6 Primary & 
secondary 
prevention of CVD 
100-160mg daily 
(n=132) or on 
alternate-days 
(n=48) 
For more than 
one month 
/retrospective 
analysis 
Serum TxB2  
Lin et al., 
2015, 
Taiwan 47 
Population-
based 
retrospectiv
e cohort 
study  
Diabetes 63.47 ± 
12.11  
Mainly secondary Cumulative 
dosage from < 
300 to ≥ 2100mg 
(n=26,494) 
• ≤ 2 times/ week 
• 3-5 times/week 
• > 5 times/week  
≤ 1 year to > 5 
years 
/retrospective 
analysis 
Incidence of 
colorectal 
cancer 
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